Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 105

1.

On the plasticizing properties of divalproex sodium: physicochemical and spectroscopic characterization studies.

Khatri P, Desai D, Minko T.

Pharm Dev Technol. 2018 Nov 6:1-10. doi: 10.1080/10837450.2018.1514049. [Epub ahead of print]

PMID:
30396305
2.

Modeling and antitumor studies of a modified L-penetratin peptide targeting E2F in lung cancer and prostate cancer.

Shaik T, Rather GM, Bansal N, Minko T, Garbuzenko O, Szekely Z, Abali EE, Banerjee D, Kerrigan JE, Scotto KW, Bertino JR.

Oncotarget. 2018 Sep 7;9(70):33249-33257. doi: 10.18632/oncotarget.26064. eCollection 2018 Sep 7.

3.

Metastatic and triple-negative breast cancer: challenges and treatment options.

Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T.

Drug Deliv Transl Res. 2018 Oct;8(5):1483-1507. doi: 10.1007/s13346-018-0551-3. Review.

4.

Molecular imaging for precision medicine.

Lu ZR, Minko T.

Adv Drug Deliv Rev. 2017 Apr;113:1-2. doi: 10.1016/j.addr.2017.08.002. No abstract available.

PMID:
28821310
5.

Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s).

Garbuzenko OB, Ivanova V, Kholodovych V, Reimer DC, Reuhl KR, Yurkow E, Adler D, Minko T.

Nanomedicine. 2017 Aug;13(6):1983-1992. doi: 10.1016/j.nano.2017.04.005. Epub 2017 Apr 19.

6.

Precision targeted therapy of ovarian cancer.

Sapiezynski J, Taratula O, Rodriguez-Rodriguez L, Minko T.

J Control Release. 2016 Dec 10;243:250-268. doi: 10.1016/j.jconrel.2016.10.014. Epub 2016 Oct 14. Review.

7.

LHRH-Targeted Drug Delivery Systems for Cancer Therapy.

Li X, Taratula O, Taratula O, Schumann C, Minko T.

Mini Rev Med Chem. 2017;17(3):258-267. Review.

PMID:
27739358
8.

Nanoparticle design considerations for molecular imaging of apoptosis: Diagnostic, prognostic, and therapeutic value.

Savla R, Minko T.

Adv Drug Deliv Rev. 2017 Apr;113:122-140. doi: 10.1016/j.addr.2016.06.016. Epub 2016 Jun 29. Review.

PMID:
27374457
9.

Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy.

Dorrani M, Garbuzenko OB, Minko T, Michniak-Kohn B.

J Control Release. 2016 Apr 28;228:150-158. doi: 10.1016/j.jconrel.2016.03.010. Epub 2016 Mar 8.

PMID:
26965957
10.

Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.

Yin PT, Shah S, Pasquale NJ, Garbuzenko OB, Minko T, Lee KB.

Biomaterials. 2016 Mar;81:46-57. doi: 10.1016/j.biomaterials.2015.11.023. Epub 2015 Nov 12.

11.

Nanotechnology approaches for inhalation treatment of lung diseases.

Kuzmov A, Minko T.

J Control Release. 2015 Dec 10;219:500-518. doi: 10.1016/j.jconrel.2015.07.024. Epub 2015 Aug 19. Review.

13.

Biodegradable Janus nanoparticles for local pulmonary delivery of hydrophilic and hydrophobic molecules to the lungs.

Garbuzenko OB, Winkler J, Tomassone MS, Minko T.

Langmuir. 2014 Nov 4;30(43):12941-9. doi: 10.1021/la502144z. Epub 2014 Oct 27.

14.

Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes.

Peddada LY, Garbuzenko OB, Devore DI, Minko T, Roth CM.

J Control Release. 2014 Nov 28;194:103-12. doi: 10.1016/j.jconrel.2014.08.023. Epub 2014 Sep 1.

15.

Dendritic silica nanomaterials (KCC-1) with fibrous pore structure possess high DNA adsorption capacity and effectively deliver genes in vitro.

Huang X, Tao Z, Praskavich JC Jr, Goswami A, Al-Sharab JF, Minko T, Polshettiwar V, Asefa T.

Langmuir. 2014 Sep 16;30(36):10886-98. doi: 10.1021/la501435a. Epub 2014 Sep 4.

PMID:
25188675
16.

Tumor-targeted responsive nanoparticle-based systems for magnetic resonance imaging and therapy.

Savla R, Garbuzenko OB, Chen S, Rodriguez-Rodriguez L, Minko T.

Pharm Res. 2014 Dec;31(12):3487-502. doi: 10.1007/s11095-014-1436-x. Epub 2014 Jun 13.

17.

Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention.

Garbuzenko OB, Mainelis G, Taratula O, Minko T.

Cancer Biol Med. 2014 Mar;11(1):44-55. doi: 10.7497/j.issn.2095-3941.2014.01.004.

18.

A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts.

Xie X, Bansal N, Shaik T, Kerrigan JE, Minko T, Garbuzenko O, Abali EE, Johnson-Farley N, Banerjee D, Scotto KW, Bertino JR.

Oncotarget. 2014 Feb 28;5(4):901-7.

19.

Nanotechnology and drug resistance.

Minko T.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1665-6. doi: 10.1016/j.addr.2013.10.005. Epub 2013 Oct 29. No abstract available.

PMID:
24177352
20.

Nanotechnology approaches for personalized treatment of multidrug resistant cancers.

Minko T, Rodriguez-Rodriguez L, Pozharov V.

Adv Drug Deliv Rev. 2013 Nov;65(13-14):1880-95. doi: 10.1016/j.addr.2013.09.017. Epub 2013 Oct 10. Review.

Supplemental Content

Support Center